Login / Signup

Risk of gastrointestinal complications in breast cancer patients treated with neratinib: a meta-analysis.

Nan JiangXiang-Wei SongJing-Jing LinZhan-Yu WangBei-Ning ZhangAo LiRu-Yi YanHong-Feng YanXiao-Yan FuJin-Lian ZhouCheng-Lin LiYan Cui
Published in: Expert opinion on drug safety (2017)
Our meta-analysis demonstrates that the neratinib arms are associated with a significantly increased risk of diarrhea and vomiting.
Keyphrases
  • systematic review
  • positive breast cancer
  • meta analyses
  • irritable bowel syndrome
  • clostridium difficile
  • chemotherapy induced
  • randomized controlled trial
  • abdominal pain
  • young adults